Tag: compensation

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 11, 2025.

SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today held its Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format. Preliminary results from the Annual Meeting indicate that two proposals were approved and two proposals were rejected by Vaxart stockholders.

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of SelectQuote, Inc. (NYSE: SLQT) resulting from allegations that SelectQuote may have issued materially misleading business information to the investing public.

SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that on June 10, 2025, the company granted inducement awards to seventeen new employees. The grants were made pursuant to Nurix’s 2024 Equity Inducement Plan as an inducement material to the employees’ acceptance of employment with Nurix and were approved by the Compensation Committee of Nurix’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4).

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of NET Power Inc. (NYSE: NPWR, NPWR.WS) between June 9, 2023 and March 7, 2025, both dates inclusive (the “Class Period”), of the important June 17, 2025 lead plaintiff deadline.

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Digimarc Corporation (NASDAQ: DMRC) between May 3, 2024 and February 26, 2025, both dates inclusive (the “Class Period”), of the important July 8, 2025 lead plaintiff deadline.

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) --

WHY: New York, N.Y., June 14, 2025. Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Elevance Health, Inc. (NYSE: ELV) between April 18, 2024 and October 16, 2024, both dates inclusive (the “Class Period”), of the important July 11, 2025 lead plaintiff deadline.

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fortrea Holdings, Inc. (NASDAQ: FTRE) between July 3, 2023 and February 28, 2025, both dates inclusive (the “Class Period”), of the important August 1, 2025 lead plaintiff deadline.

SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 26,000 shares of the Company’s stock (the “Inducement Grant”) to newly hired employees on June 10, 2025 (the “Grant Date”), in connection with the commencement of employment.

CALGARY, Alberta, June 13, 2025 (GLOBE NEWSWIRE) -- Peyto Exploration & Development Corp. (TSX: PEY) ("Peyto") announces the retirement of Michael (Mick) MacBean as a director and confirms the monthly dividend with respect to June 2025 of $0.11 per common share is to be paid on July 15, 2025, for shareholders of record on June 30, 2025. Dividends paid by Peyto to Canadian residents are eligible dividends for Canadian income tax purposes.